Ambio Life Sciences Launches World’s First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions

In this episode of Global Economic Press, Alex Brady discusses a pioneering initiative by Ambio Life Sciences, which has launched the world's first clinical ibogaine program for patients with neurodegenerative conditions. This groundbreaking program, which began in February 2025, aims to provide a new avenue for treatment beyond traditional symptom management for conditions such as Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The program is designed to safely accommodate patients seeking ibogaine treatment and to gather real-world data that could inform future research and care. Ambio Life Sciences' Chief Executive Officer, Jonathan Dickinson, emphasizes the potential of ibogaine to support brain healing in ways not fully understood today.

The program has already supported 30 patients and is delivered by a multidisciplinary team in facilities equipped to meet the mobility and safety needs of participants. Notable early participants include country music artist Clay Walker and National Football League Hall of Famer Brett Favre, both of whom have reported positive changes in their conditions. The program does not claim to cure neurodegenerative diseases but offers a supportive environment for exploring ibogaine as part of a broader health management strategy. Ambio Life Sciences is also conducting preclinical research in partnership with Dalhousie University to further understand ibogaine's effects on neuroinflammatory biomarkers and disease models. For more information on the program or to apply, visit Ambio Life Sciences' website.